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Renal injury has been recognized as an increasingly prevalent
complication of liver transplantation (LT) over the last decade.
Both acute and chronic renal injuries occur with high frequency
in liver transplant recipients and are associated with increased
morbidity and mortality. The risk of immediate post-LT kidney
dysfunction is increased in patients with pre-transplant kidney
failure, hepato-renal syndrome (HRS), and intra-operative or
post-operative hypotension. Thus with the improvement in life
expectancy after LT, chronic kidney disease (CKD) has emerged
as an increasingly prevalent complication among long-term sur-
vivors. Although post-LT renal injury is often multifactorial, one
of the dominant mediators is the use of calcineurin inhibitors
(CNI), namely Cyclosporine (CsA) and Tacrolimus (Tac), which
are the cornerstone of immunosuppression in LT recipients. These
drugs indeed intrinsically share a variety of renal toxicities, rang-
ing from oligoanuric acute renal failure to chronic kidney disease.
Optimization of immunosuppression for protection of kidney
function must, therefore, be considered a major goal after LT, in
particular for patients with already impaired renal function.
The aim of this article is to review the epidemiology, risk fac-
tors, and consequences of post-LT renal dysfunction and to dis-
cuss the current approaches to overcome CNI toxicity after LT,
both in the early post-operative period and in the long-term,
focusing on manipulation of immunosuppressive agents.
The issue of combined liver/kidney transplantation in LT can-
didates with renal failure is beyond the scope of this review and
will not be considered herein.Journal of Hepatology 20
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period
The issue of early renal dysfunction after liver transplantation
Acute post-operative renal injury frequently occurs after LT [1–
6], The high frequency of acute renal dysfunction results from
variable, multi-factorial insults to the kidney, including pre-
existing hepato-renal syndrome, the use of nephrotoxic antimi-
crobial agents and, obviously, the use of CNI immediately after
LT. In fact, one of the strongest predictors is the dose and level
of CNI in the early post-transplantation period [7,8]. An impor-
tant objective in the early post-operative period is, therefore, to
optimize the immunosuppressive regimen in order to protect
kidney function and prevent long-term consequences.
Depending on the criteria used to deﬁne ‘‘acute renal failure,’’
post-operative renal injury has been reported in 17–94% of
patients undergoing LT [1–6]. Using the RIFLE (Risk–Injury–
Failure–Loss–Endstage) criteria (Table 1) for acute renal dysfunc-
tion, renal ‘‘injury’’ (increase in serum creatinineP2.0  baseline
or decrease in GFR P50%) was observed in 41.5% of the patients
in the ﬁrst month post-LT [7]. In two studies, in which renal fail-
ure was deﬁned by an increase in serum creatinine P50% above
baseline values, the incidence of renal failure was 42% and 48%
[5,6].
Severe forms of acute renal ‘‘failure’’ (RIFLE) requiring renal
replacement therapy (RRT) have been reported in 6.5–18.3% [9–
12,4,13] of cases, usually early, within the ﬁrst week post-LT. In
this setting, acute renal failure results from major post-operative
stresses frequently associated with acute tubular necrosis,
including prolonged hypotension, sepsis or septic shock, sus-
tained pre-renal failure, primary graft non-function, or delayed
function of the liver.
Post-operative renal injury is responsible for signiﬁcant mid-
and long-term consequences and impacts both on kidney func-
tion and survival. Renal replacement therapy has consistently
been associated with a signiﬁcant reduction in 1-year survival
compared to patients not requiring RRT: 1-year survival in RRT
patients is close to 50% (Fig. 1) [9,12]. Among survivors, RRT is
considered a signiﬁcant predictor of impaired renal function in
the long term, with a more than 2-fold increase in the risk of
chronic renal failure [14]. Early acute renal injury not requiring
RRT is also considered a major contributor to the long-term risk
of chronic kidney disease [8,15,16]. In most studies, early11 vol. 54 j 1041–1054
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Fig. 1. Probability of survival after liver transplantation according to dialysis
in the early post transplant period (p = 0.0001). Adapted from Singh et al. [12].
Table 1. The acute dialysis quality initiative (ADQI) criteria for the deﬁnition and classiﬁcation of acute kidney injury: the RIFLE (Risk–Injury–Failure–Loss–Endstage
renal disease) criteria*.
ELFIR
category   
Serum creatinine criteria Urine output criteria
ksiR Increase in serum creatinine ≥1.5 x baseline or decrease in GFR ≥25% <0.5 ml/kg/h for ≥6 h 
Injury Increase in serum creatinine ≥2.0 x baseline or decrease in GFR ≥50% <0.5 ml/kg/h for ≥12 h 
Failure Increase in serum creatinine ≥3.0 x baseline  or decrease in GFR ≥75% 
or an absolute serum creatinine ≥354 µmol/L with an acute rise of at least 44 µmol/L 
<0.3 ml/kg/h ≥24 h or anuria ≥12 h 
RIFLE classiﬁcation is an attempt to deﬁne the presence or absence of the clinical syndrome of acute kidney injury in a given patient, and to describe the severity of this
syndrome.
* In Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P: Acute Dialysis Quality Initiative workgroup: acute renal failure – deﬁnition, outcome measures, animal models,
ﬂuid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care
2004;8:R204–R212.
Reviewelevation in serum creatinine at 1, 3, or 6 months post-LT was an
independent predictor of chronic renal failure [8,15,16]. And in a
recent retrospective study [17] of 1075 patients, the onset of
chronic renal dysfunction within the ﬁrst year after LT was even
correlated with reduced survival.
Limiting early insults of any kind to the kidney and especially
CNI toxicity is, therefore, of major importance in order to pre-
serve renal function and survival in the long-term. With respect
to this, understanding the mechanism of CNI nephrotoxicity is
essential.
Mechanism of acute CNI renal toxicity and the relationship with end-
stage liver disease
Cyclosporine and Tac are two CNI which share a similar mecha-
nism of action, as well as a pattern of nephrotoxicity. Acute CNI
nephrotoxicity is caused by an intense, predominantly afferent,
arteriolar vasoconstriction (Fig. 2) which thereby alters renal
hemodynamics (reviewed in [18,19]. This pre-renal, dose-related,
renal dysfunction results in an acute and reversible decrease in
the glomerular ﬁltration rate (GFR), renal blood ﬂow, and urine
output. The vasoconstriction is in part related to an imbalance
in the release of vasodilator substances, such as prostaglandin
E2 [20] or NO [21], and increased vasoconstrictor factors, such1042 Journal of Hepatology 2011as thromboxane A2, endothelin 1 [22], and angiotenisin II [20].
Local activation of the sympathetic nervous systemmay also con-
tribute. Following discontinuation of CNI, renal function usually
returns to baseline without any major histological or cytological
abnormalities. However, in some instances, prolonged vasocon-
striction may directly damage renal tubular cells causing acute
tubular vacuolization (Fig. 3) or necrosis, with subsequent
tubule-interstitial lesions and chronic/irreversible nephrotoxicity
[19].
Immunosuppressive approaches to prevent acute renal dysfunction
Prevention of acute CNI nephrotoxicity can in principle be
achieved by: (A) excluding CNI from immunosuppressive regi-
mens; (B) delaying the introduction of CNI beyond the very early
post-operative phase during which the kidney is particularly sus-
ceptible to CNI acute injury; and, (C) early minimization of CNI
levels.
Excluding CNI from immunosuppression
Withdrawing CsA in patients with HRS or signiﬁcant renal dys-
function and replacement with Azathioprine and steroids was
ﬁrst proposed [23] in the early nineties. Such an approach must
be used with caution in the early post-operative phase because
elimination of CNI even when substituted by more recent anti-
proliferative agents than Azathioprine, such as MPA has been
associated with a notable rate of rejection [24,25] and even graft
loss.
Sirolimus and Everolimus are two mammalian targets of Rap-
amycin inhibitors (mTOR) which when given without CNI in
patients with normal baseline renal function are not considered
nephrotoxic. Yet, mTOR inhibitors are usually avoided in the
immediate post-LT period. A pivotal study combining Sirolimus
and Tacrolimus as a primary immunosuppressive regimen dem-
onstrated a signiﬁcant reduction in 1-year survival because of
an unexpected incidence of infections and vascular thrombotic
complications. In addition, wound healing complications may
also be caused by the antiproliferative effects of this class of
agents. For these reasons, very early use of mTOR inhibitors
post-LT cannot yet be recommended. However, a study in 145
liver transplant recipients on maintenance regimens supported
that concentration-controlled Everolimus allows for the elimina-
tion of CNI without increasing the risk of acute rejection [26].
Early introduction of mTOR inhibitors, 4 weeks post-LT, followedvol. 54 j 1041–1054
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Fig. 2. Schematic representation of the pathophysiology of calcineurin inhibitors nephrotoxicity. Reprinted from Naesens et al. [45], with permission from the
American Society of Nephrology.
JOURNAL OF HEPATOLOGYby early reduction or discontinuation of CNI may provide supe-
rior renal function compared to CNI-based standard therapy
and, is currently under investigation (Clinical Trials.gov identi-
ﬁer: NCT00622869).
Another option which has achieved encouraging results in
kidney transplantation [27] is the blockade of the T-cell co-
stimulation pathway. Belatacept is a fusion protein derived from
CTLA4-Ig which blocks the interactions of CD28 with CD80 and
CD86 with a 10-fold greater inhibition of T-cell activation
in vitro as compared with CTLA4-Ig alone. In kidney transplanta-
tion, a Phase II study involving 218 recipients of de novo renal
allografts compared the efﬁcacy of Belatacept to CsA as a mainte-
nance immunosuppressant together with Basiliximab induction,
steroids, and MPA [27]. Belatacept-based therapy (intravenous
infusion every 4 or 8 weeks) showed similar efﬁcacy in prevent-
ing acute rejection at 6 months versus CsA-based treatment:
6–7% for Belatacept versus 8% for CsA. Furthermore, Belatacept-
treated patients showed a signiﬁcant improvement in renal func-
tion at one year compared with CsA-treated patients (63 ml/mn
versus 53.5 ml/mn/1.73 m2). Whether such a beneﬁcial impactJournal of Hepatology 2011on renal function can be achieved in LT recipients on mainte-
nance Belatacept therapy is currently being investigated (Belata-
cept in liver transplantation; Clinical Trials.gov identiﬁer:
NCT00555321).
Delaying introduction of CNI (Table 2)
The challenge of such an approach is to ensure adequate immu-
nosuppression despite delayed introduction of CNI. To achieve
this goal, induction therapy with anti-lymphocyte/thymocyte
antibody preparations or anti-interleukin-2-receptor antibodies,
with or without MPA have been proposed (Table 2). This
approach can be particularly useful in instances where pre- or
immediate post-LT renal function is signiﬁcantly altered.
Anti-lymphocyte antibodies
In a retrospective study [28] comparing 129 patients receiving
standard CNI, with 262 patients receiving 3-day induction
therapy with Thymoglobulin (2.5 mg/kg/d) followed by CNI
introduction as the local standard prophylactic treatment,
Soliman and colleagues reported better renal function at 1-yearvol. 54 j 1041–1054 1043
Table 2. Impact of induction therapies and delayed introduction of calcineurin inhibitors on renal function after [28,30–33]. [36]
References No. 
Patients  
Design Time of IS 
change 
Type  
of induction  
Immunosuppression
/groups  
Acute 
rejection  
Renal function 
Soliman  
et al. 
[29] 
391  Retrospective, 
controlled 
De novo  ATG  A (n = 129): CNI 
B (n = 262): delayed
CNI + ATG  
A: 31.8%  
B: 14.5%  
p = 0.0008
A: 72 ml/min
B: 81 ml 
p = 0.02 , at 1 yr
Bajjoka 
et al.
et al.
[30] 
198  Retrospective  
2 consecutive 
arms 
De novo  ATG  A (n = 118) : delayed 
CNI + ATG + MMF
B (n = 80) : standard 
CNI 
A : 57.4 ml/min/1.73 m2
B: 43.7 ml/min/1.73 m2
p <0.001, at 1 yr 
Lin  
]13[
47 Prospective 
non randomized  
Open label 
De novo  IL2 R Ab 
basiliximab  
A (n = 27) : delayed 
CNI + IL2R Ab + MMF
B (n = 18) :  CNI + 
MMF therapy 
A: 72 ml/minute 
B :  57 ml/minute, 
p = 0.04
Yoshida 
et al.
[32] 
148  Prospective, 
controlled 
De novo bAR2LI
daclizumab
A (n = 72): MMF + 
delayed 
reduced TAC + IL2 R Ab 
B (n = 76): MMF + 
esodlamron
TAC + IL2R Ab
Month 1 
A: 86.8 ml/min 
B: 70.1 ml/min
p <0.001
Still significant at M6
Neuberger
et al. 
[33] 
485  Prospective 
Randomized 
Multicenter 
3 arms 
ovoneD bAR2LI
bamuzilcad
lower BPAR in
group C:
p = 0.0054
A: 23.2%
B: 27.7%
p = 0.68  
At 1 yr 
Reduction in  GFR
lower in group C vs 
A and B 
13.6 vs 23.6 vs 21.2
ml/mn, p = 0.007 
A: Standard Tac + 
IL2R Ab 
B: MMF + reduced 
Tac + IL2 
C: MMF + reduced 
delayed Tac + IL2  
CNI, calcineurin inhibitors; IL 2R Ab, IL2 receptors Antibodies; ATG, anti-thymocyte globulins; MMF, mycophenolate mofetil. Overall, delayed-reduced introduction of CNI,
in combination with induction therapy + MMF was associated with an improvement in renal function without increasing the risk of rejection in the short and mid-term.
Reviewin the Thymoglobulin induction group (GFR: 81 versus 72
ml/min, p = 0.02). In addition, Thymoglobulin patients experi-
enced less frequent rejection with similar 1-year survival and a
similar incidence of de novo tumors. Interestingly, the same group
recently reported that a longer (10-day) Thymoglobulin-based
induction therapy [29] was associated with an increased risk of
infection, supporting the concept that the best risk–beneﬁt ratio
was achieved with the short induction phase. Similar results were
observed by Bajjoka et al. [30]. In this study, all the patients had
post-operative renal dysfunction deﬁned by the need for
hemodialysis or a creatinine >1.5 mg/dl, and received MPA.
Anti-thymocyte globulin (0.5–1 mg/kg/d) was given for a maxi-
mum of 5 days or until creatinine had decreased <1.2 mg/dl.
Delayed CNI initiation after anti-thymocyte globulin induction
was associated with a signiﬁcant improvement in renal function
with a higher estimated glomerular ﬁltration rate (57.4 versus
43.7 ml/min/1.73 m2, p <0.001) and less dependence on dialysis
(0.8% versus 13%, p <0.001) at 12 months post-transplant, with
no impact on CMV infection or severity of HCV recurrence.
Anti-interleukin-2-receptor antibodies
When complexed with anti-IL2 receptor antibodies, IL-2 recep-
tors on T-lymphocytes are no longer available for IL-2 binding,
and the proliferation of associated T-lymphocytes is inhibited.
The duration of IL-2 receptor saturation in adults is longer than
4 weeks and several studies have tested whether a delayed
introduction of CNI after Daclizumab or Basiliximab induction
therapy was beneﬁcial to kidney function. In a prospective non-
randomized open label study [31], 47 consecutive living donor1044 Journal of Hepatology 2011LT recipients were treated either with Basiliximab induction ther-
apy + MPA and delayed introduction of Tacrolimus, or with con-
ventional CNI + MPA therapy. Basiliximab was preferentially
used in the sickest patients at transplantation and in those with
signiﬁcant blood loss. In such cases, Tac was introduced as a med-
ian of 36 h post-LT [24–108 h]. The creatinine clearance rate was
higher (median 72 versus 57 ml/min, p = 0.04) and the incidence
of renal insufﬁciency was lower in the induction group (26% ver-
sus 67%, p <0.01) at three months post-transplant.
A beneﬁcial impact of delayed introduction of CNI on renal
function in patients receiving Daclizumab induction therapy
has also been reported in two randomized controlled studies
[32,33] (Table 2) without increasing the risk of rejection. In both
studies, Daclizumab was given in combination with MPA, fol-
lowed by delayed introduction of Tac at normal or even reduced
doses. In the Yoshida and colleagues study [32], GFR calculated
by the Modiﬁcation of Diet in Renal Disease [34] method was sig-
niﬁcantly better in the delayed, low-dose (4–8 ng/ml) Tac group
than in the standard Tac group, at 1 week, 1 and 6 months
post-LT. In the ReSpECT trial [33], the decrease in GFR [ml/min]
from baseline to week 52 was signiﬁcantly lower in the induc-
tion/delayed–reduced Tac group than the standard group (GFR
reduction: 13.63 ml/min versus 23.61 ml/mn, p = 0.007). Renal
replacement therapy was also required less frequently in the
induction group (4.2% versus 9.9%; p = 0.037).
In conclusion, these results highly suggest that delayed-
reduced introduction of CNI under the protection of MPA and
anti-IL2 receptor antibodies is associated with an improvement
in renal function in the short and mid-term, without increasingvol. 54 j 1041–1054
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the risk of rejection when compared with conventional CNI-based
immunosuppression.
Minimizing CNI doses: combining reduced doses of CNI with MPA
MPA is a non-competitive reversible inhibitor of IMPDH, an
enzyme required for de novo purine synthesis, which selectively
inhibits lymphocyte proliferation without nephrotoxicity.
The combination of MPA and reduced Tac has been proven to
be an efﬁcacious and well tolerated immunosuppressive regimen
in large randomized, multicenter studies. Investigated as a spe-
ciﬁc trial arm in the ReSpECT trial [33], the minimized Tac triple
therapy (MPA, 2 g/day + reduced-dose Tacrolimus with target
trough levels 68 ng/ml + corticosteroids) showed similar efﬁcacy
in preventing rejection than the standard dual group (Tacrolimus
with target trough levels >10 ng/ml and corticosteroids) with
only a marginal, non-signiﬁcant reduction in GFR at 52 weeks
(21.22 versus 23.61 ml/min).
In summary, liver transplant recipients, especially those with
severe end-stage liver disease and those with early post-
operative complications, are exposed to a high risk of early renal
dysfunction, which is predictive of chronic renal injury. In this
setting there is a growing body of evidence that earlyAfferent arteriole 
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Glomerulus 
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Fig. 3. Renal injury after liver transplantation. Role
Journal of Hepatology 2011manipulation of immunosuppression with delayed introduction
of CNI, under the protection of induction therapy and MPA, is
beneﬁcial to the kidney in the short-term, and, therefore, proba-
bly in the long-term, without increasing the risk of rejection. The
reasons for this impact have not been fully elucidated.
As stated above, pre-transplant renal failure, in particular HRS,
is a predictor of post-transplant renal dysfunction. Since HRS is
one of the most common causes of renal failure pre-LT [35] and
is characterized by a pre-renal dysfunction with intense arterial
vasoconstriction, it can be reasonably hypothesized that HRS
patients and to a lesser extent ascitic patients, could be more sus-
ceptible to the vasoactive effects of CNI post-transplant. These
patients, therefore, could be more prone to develop acute CNI-
induced nephrotoxicity and even tubular cell injury. Delayed
introduction or even avoidance of CNI might be particularly pro-
tective to the kidney in the short term, resulting in a beneﬁcial
effect in the long-term. To prevent nephrotoxicity, immunosup-
pression could be tailored to each patient and the impact of indi-
vidualized immunosuppressive regimens tested in speciﬁc
populations.
In patients with HRS, interleukin 2 receptor blockers or short-
term antithymocyte globulin induction therapy + MPA, with
delayed, reduced-dose CNI could be proposed. In LT candidatesCalcineurin inhibitors 
Acute toxicity  
intense, predominantly afferent, 
arteriolar vasoconstriction  with 
early thickening of the intima 
Chronic toxicity
Afferent arteriolar hyalinosis & 
sclerosis, resulting in narrowing of 
arteriole lumen  
Tubule 
Calcineurin inhibitors 
Acute tubular toxicity 
Inconstant swelling of 
proximal tubular cells 
Chronic toxicity 
tubular atrophy  
and interstitial fibrosis   
of calcineurin inhibitors and other co-factors.
vol. 54 j 1041–1054 1045
Review
with refractory ascites, but apparent normal renal function pre-
LT, low-dose CNI in conjunction with MPA and standard steroid
therapy could be considered. Standard immunosuppression could
be used in elective situations in patients with strictly pre- and
post-LT normal kidney function (Fig. 4 summarizes the options
for protecting the kidney in the early post-operative phase).Immunosuppression in liver transplant patients with chronic
renal injury in the long-term
The issue of renal dysfunction in the long-term
Deﬁnition and frequency
Chronic renal impairment is one of the major complications after
LT and is largely caused by prolonged exposure to CNI. Renal
impairment is associated with increased risks of morbidity and
mortality after transplantation and one of the major long-term
goals is to prevent renal function deterioration.Table 3. Chronic kidney diseases: the KIDIGO classiﬁcation. [38]
noitpircseDegatS GFR, ml/min 
per 1.73m
1  Kidney damage with normal or increased GFR 90 
2  Kidney damage with decreased GFR 60-89 
3  Moderately decreased GFR 30-59 
4  Severely decreased GFR 15-29 
5  Kidney failure <15 (or dialysi
GFR, glomerular ﬁltration rate.
Patients with 
renal dysfunction
pre LT (HRS) or 
early post LT
Consider indu
(basiliximab o
delayed/reduc
Patients at risk of
renal dysfunction
pre LT (refractory ascitis)
or post LT
Consider redu
CNI doses + M
anti-CD25-bas
Patients with 
normal renal function
Consider conve
based regimen
reduced CNI +
therapy
Fig. 4. Protection of the kidney in the early post-operative period: how to tailor
thymocytes globumins; CNI, calcineurin inhibitors; HRS, hepato-renal syndrome; LT, liv
1046 Journal of Hepatology 2011The deﬁnition and classiﬁcation of chronic kidney disease
[CKD] has been recently revised by the Kidney Disease Improving
Global Outcome conference [37,38]. Chronic Kidney Disease is
deﬁned by ‘‘structural or functional abnormalities of the kidney,
with or without decreased GFR, evidenced by abnormalities in
the composition of the blood or urine, or abnormalities in imag-
ing tests,’’ or GFR <60 ml/mn/1.73 m2, with or without kidney
damage. The K/DOQI–KIDIGO classiﬁcation of CKD stratiﬁed renal
alterations into ﬁve stages which are summarized in Table 3.
The exact prevalence of CKD in LT is difﬁcult to determine
because it varies widely according to the deﬁnition of CKD and
length of follow-up (1–13 years), but appears to range between
4% [39] and 79% [40]. In some reports [39,41] the deﬁnition of
CKD relies on serum creatinine, which is not appropriate for eval-
uating renal function if not interpreted together with sex, age,
and weight. Others use GFR but with different methods of esti-
mation and with non-standardized cut-off values. For instance,
according to Cohen et al., the prevalence of GFR <40 ml/min/
1.73 m2 as determined by iothalamate clearance was 27.5% atRelated terms 
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Albuminuria, Proteinuria, Hematuria
Chronic renal insufficiency, early renal insufficiency
Chronic renal insufficiency, late renal insufficiency 
pre end stage renal disease 
s)  Renal failure, end stage renal disease, uremia 
ction therapy
r ATG) + MMF +
ed CNI
Expected improvement in 
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ced
MF or 
ed induction 
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increasing rejection.  
To be tested in specific 
trials
ntional CNI
 or 
 MMF
immunosuppression to the individual proﬁle of the LT recipient? ATG, anti-
er transplantation; MMF, mycophenolate mofetil.
vol. 54 j 1041–1054
Table 4. Frequency of chronic kidney disease in liver transplant recipients according to calculated GFR and K/DOGI-K/DIGO [6,14,43,44] (for classiﬁcation see
Table 3).
Study Number of 
stneitap
tniopdnE GFR 
assessment
Frequency of CKD 
according to stage
Ojo AO et al.  
[15]  
948,63 5-year cumulative incidence MDRD Stage 4 = 18.1% 
O’Riodan A et al. 
[44] 
230 10-year cumulative incidence MDRD
Stage 1 = 9.6%
Stage 2 = 53.7% 
Stage 3 = 56.7% 
Stage 4 = 6.1% 
Stage 5 = 2.6% 
Burra P et al.  
[45]  
322 5-year prevalence ND Stage 3 = 36% 
Stage 4 = 2.7% 
Karie-Guigues J et al. 
[6]  
1508 5-year prevalence MDRD
Stage 1 = 5.7%
Stage 2 = 36.6% 
Stage 3 = 52.7% 
Stage 4 = 3.7% 
Stage 5 = 1.3%
CKD, chronic kidney disease; GFR, glomerular ﬁltration rate; ND, not determined; MDRD, modiﬁcation of diet in renal disease.
JOURNAL OF HEPATOLOGY5-years [42], while Sheiner et al. [40] reported that the preva-
lence of GFR <43 ml/min/1.73 m2 was 79.5% at 5-years. In the lat-
ter study, renal function was estimated using the Cockroft–Gault
formula and standardized to a body surface area of 1.73 m2 [40].
Because of these major discrepancies, a better estimation is
given in cohort studies in which the frequency of CKD has been
assessed according to a calculated GFR [6,14,43,44]. The fre-
quency of CKD after LT as reported in major cohort studies is
described in Table 4. In the largest study based on the analysis
of 36,849 liver transplant recipients, Ojo et al. reported a cumu-
lative incidence of advanced CKD (deﬁned as GFR 6 29 ml/min/
1.73 m2 as assessed by the aMDRD formula) of 8.0% at 1-year
and 18.1% at 5-years. This incidence was higher than in heart,
lung, or heart–lung transplant recipients [14]. Overall, these
results indicate that deterioration of renal function almost uni-
versally occurs after LT. On average, moderate but signiﬁcant
renal dysfunction (Stage 2–3) occurs in 40–50% of LT recipients
and severe renal dysfunction (Stage 4) in 5–15% of patients,
5 years post-LT.Mechanism of CNI-chronic renal injury
CNI not only induces reversible alterations in renal vascular resis-
tance, but is also associated with irreversible damage to the renal
architecture. Detailed histological analyses have shown the three
compartments of kidney that can be irreversibly injured by both
CsA and Tac treatment: vessels (arteriolar hyalinosis), tubulo-
interstitium (tubular atrophy and interstitial ﬁbrosis), and glome-
ruli (thickening and ﬁbrosis of Bowman’s capsule and focal seg-
mental or global glomerular sclerosis) (Figs. 2 and 3) [45]. The
mechanism of chronic CNI nephrotoxicity has been studied
extensively. A combination of CNI-induced hemodynamic
changes and direct effects on tubular epithelial cells is thought
to play a role. Nodular hyaline deposits in the media of afferent
arterioles (arteriolar hyalinosis) are regarded as a hallmark of
CNI nephrotoxicity. Arteriolar hyalinosis is commonly regardedJournal of Hepatology 2011as irreversible, although it has been reported that complete
regression of severe CsA-associated arteriolopathy can occur after
stopping or reducing CsA exposure following kidney transplanta-
tion [46]. In the setting of chronic use of CNI, it is likely that nar-
rowing of the arteriolar lumen is a major contributor to the
development of interstitial ﬁbrosis and tubular atrophy, as well
as glomerular sclerosis (Fig. 3).
Other risk factors of CKD post-LT
In combination with CNI toxicity, pre-transplant renal dysfunc-
tion [47] and early post-operative renal injury are probably the
most important predictors of post-transplant CKD. Yet, the onset
of CKD after LT is usually multifactorial, also promoted by hyper-
tension, diabetes mellitus, hepatitis C virus, and even alcohol
intake [6,14,43,44,47,48]. The impact and site of action of these
co-factors are summarized in Fig. 3.
Impact on outcome
Several reports indicate that chronic renal alterations signiﬁ-
cantly impact on morbidity and mortality after LT. Ojo et al.
found that non-renal solid organ transplant recipients with CKD
had a 4.55-fold increase in the risk of death, compared to trans-
plant recipients without CKD [14]. Moreno et al. reported that
6-year survival was signiﬁcantly lower among liver transplant
patients with CKD than those without (63% versus 71%) [49].
Gonwa et al. reported that the 13-year survival rate in patients
with severe CKD was only 28.2% compared to 54.6% in those
without post-transplant CKD [8].
The long-term management of CKD after LT
Optimal management of CKD post-LT relies ﬁrst on prevention:
early CNI minimization, aggressive blood glucose, and blood pres-
sure controls and treatment of HCV infection when appropriate.
In the case of hypertension, two classes of antihypertensive drugsvol. 54 j 1041–1054 1047
Table 5. Calcineurin inhibitors reduction (at least 50%) with introduction of mycophenolic acid.
Reference N Design Time of  
IS change 
Baseline Creatinine Baseline 
GFR (ml/mn)
Follow up
(years)
% of pts with 
renal function
improvement *
Rejection*
N (%) 
Cantarovich M         
2003  
[51]  
19 Uncontrolled 
ydutsesac
1 year  141 ± 24 mol/L 53 ± 9 1  90  5/19 (29)
Koch MO  
2004  
[52]  
32 Uncontrolled 
ydutsesac
25.6 ± 34.7 
months 
2.63 ± 0.39 mg/dl ND 886.0±8.4 2/32 (6)
Reich DJ   
2005  
[53]
18 Prospective 
dezimodnar
ld/gm8.1shtnom31 46.7 ± 11.8 1  50  2/18 (11)
Créput C             
2007  
[54]  
49 Prospective 
dellortnocnu
7.7 ± 4.3  ND 085.1±4.341±9.24 0 
Pageaux GP             
2006  
[55]  
56
MMF/C :
27/29
Prospective 
dezimodnar
1 year  172 mol/L 43 1  72  0 
Cicinatti VR             
2007  
[56]  
75 
MMF/C:
50/25
Prospective 
dezimodnar
72.4 ± 54.9 
months 
1.9 ± 0.4 mg/dl ND 1  62  ND 
Biselli M  
2009  
(57) 
60 
MMF/C:
30/30
Prospective 
dellortnoc
62.5 
months
 1.65 mg/dl 51 2  53  0 
post Tx
post Tx
years
CN, calcineurin inhibitors; MMF, Mycophenolate mofetil; IS, immunosuppression; GFR, glomerular ﬁltration rate. In the ﬁve controlled studies in which this approach was
tested, the incidence of rejection ranged from 0–11%, for a crude number of rejection episodes of 2/234 patients (8/). Taking into account all the available studies, 10
rejection episodes occurred in 285 patients, for an incidence of 3.5%. This approach was associated with an improvement in renal function, although modest, in 50–90% of
the cases.
Reviewmay be beneﬁcial to prevent CNI renal toxicity (reviewed in [45]):
on the one hand, vasodilatators as calcium channel blockers may
counteract the vasoconstrictive effects of CNI and prevent the fall
in renal plasma ﬂow and GFR associated with CNI administration.
On the other hand, ACE inhibitors and angiotensin II receptor
blockers could counteract the pivotal role of the renine angioten-
sin system in the development of CNI nephrotoxicity. Spironolac-
tone could as well counteract the pivotal role of aldosterone.
Early detection of renal injury is also required based on careful
assessment of renal function. This includes sequential monitoring
of serum creatinine and assessment of calculated glomerular ﬁl-
tration rate at least every 6 months, in combination with sequen-
tial measurements of proteinuria and hematuria, and in patients
without proteinuria, measurement of microalbuminuria. In
patients in whom renal dysfunction is detected, a strict coopera-
tion with a nephrologist is mandatory. There is currently no
guideline regarding the place of renal biopsy in the setting of kid-
ney injury after LT. The decision should be taken on a case by case
basis, taking into account associated co-morbidities, timing, and
course of renal dysfunction as well as the risk/beneﬁt ratio of kid-
ney biopsy. Kidney biopsy should be particularly considered in
the case of early rapid dysfunction with signiﬁcant proteinuria,
or on the long term in patients with proteinuria >1.5 g/24 h, espe-
cially in HCV-infected patients, to differentiate between CNI and
HCV-related injury. Indeed, in the case of HCV-related injury, IFN1048 Journal of Hepatology 2011based-antiviral therapy may be considered instead of CNI mini-
mization. In patients with early stages of renal injury (Stages 1
and 2 of the KIDIGO classiﬁcation), measures to protect the kid-
ney must be undertaken including the use of ACE inhibitors
and angiotensin II receptor blockers, further minimization of
CNI and if possible conversion to non-nephrotoxic immunosup-
pressive agents.
CNI minimization protocols
CNI minimization protocols have been intensively developed and
evaluated in an attempt to stabilize and even improve renal func-
tion and patient outcome in LT recipients [36]. Non-nephrotoxic
immunosuppressive drugs, such as azathioprine, MPA, and mTOR
inhibitors (i.e. Sirolimus and Everolimus) have been studied
according to two approaches: CNI reduction with introduction
of non-nephrotoxic agents, and CNI withdrawal with replace-
ment by non-nephrotoxic drugs. Of note, the approaches dis-
cussed below, including subtherapeutic levels of CNI or CNI
withdrawal together with MPA or mTOR inhibitors have been
proposed to be licensed.
CNI reduction
Beneﬁcial effects of MPA combined with CNI minimization have
been reported in several studies [48–54]. The results of these
studies are summarized in Table 5. Most enrolled a small numbervol. 54 j 1041–1054
Table 6. Calcineurin inhibitors withdrawal and replacement by mycophenolic acid.
Reference 
Schlitt HJ   
2001  
[24]  
Barkman A   
2000  
[58]  
Raimondo ML  
2003  
[59]  
Moreno-P  JM 
2004 
[60]  
Reich DJ   
2005  
[53]  
Dharancy  S   
2009  
[61]  
N 
82
MMF/C:
14/14
22
54
MMF/C:
16/29
05
02
25
Design  
Prospective 
randomized
Prospective 
uncontrolled
Prospective
Case-control
Uncontrolled
Prospective 
uncontrolled 
Retrospective 
Uncontrolled 
Time of IS 
egnahc
(months)
≥6 
>6 
45 
18
16 
70 ± 53 
Baseline 
Creatinine
168.1 mol/L
201 mol/L 
179 mol/L
1.8 mg/dl
1.8 mg/dl
DN
Baseline 
GFR
(ml/mn)
05
DN
DN
44.7
35
37 ± 10
Follow up
(months)
6 
15 
35 
18 
21
42
% of pts with 
renal function
improvement *
87
47
26
08
36
68
Rejection*
N (%) 
3/14 (21)
2/22 (5)
1/16 (6)
6/50 (12)
6/20 (30)
2/52 (3)
CNI, Calcineurin Inhibitors; MMF, Mycophenolate Mofetil; C, control; IS, immunosuppression; GFR, glomerular ﬁltration rate; Tx, Transplantation. ⁄ In MMF group. CNI
withdrawal followed by MMF monotherapy was associated with a higher risk of rejection (21% to 30%) and sometimes leading to graft loss, in the 2 randomized controlled
studies in which monotherapy was started early post-LT. In the retrospective studies with late CNI withdrawal, the risk of rejection was lower, ranging from 3 to 12%. A total
of 22 rejection episodes were observed in 188 patients for an incidence of 12%. An improvement in renal function was observed in 74% of the cases.
JOURNAL OF HEPATOLOGYof patients with moderate renal impairment [Stage 3 in K/DOQI–
KDIGO classiﬁcation] at the time of MPA introduction. With an
average follow-up of one year, these studies showed that intro-
duction of MPA combined with at least a 50% reduction in CNI
dosage was associated with a signiﬁcant improvement in renal
function and a low risk of biopsy-proven rejection. In MPA stud-
ies, the overall incidence of acute rejection was 3.5%, and only
0.8% in the MPA arm of the randomized controlled studies.
In a prospective randomized study [52] we investigated the
effects of MPA introduction followed by reduction in CNI dose
on renal function in patients who had developed CNI-related
CKD more than 1-year post-LT. Fifty-six patients were randomly
assigned to receive MPA followed by at least a 50% CNI dose
reduction (n = 29), or CNI without addition of MPA (n = 27). In
the MPA group, there was a signiﬁcant decrease in serum creati-
nine values from 171.7 ± 24.2 lmol/l at day 0 to 143.4 ± 19 lmol/l
at month 12 and a signiﬁcant increase in creatinine clearance
from 42.6 ± 10.9 to 51.7 ± 13.8 ml/mn. No episode of rejection
was observed. In the control group, there was no improvement
in renal function. That is, serum creatinine values of
175.4 ± 23.4 lmol/l at day 0 and 181.6 ± 63 lmol/l at month 12,
and creatinine clearance of 42.8 ± 12.8 ml/mn at day 0 and
44.8 ± 19.7 ml/mn at month 12 were observed. The differences
between the two groups were signiﬁcant (p = 0.001 for serum
creatinine, and p = 0.04 for creatinine clearance). It must be
emphasized that improvement in renal function was observed
early after CNI reduction, usually during the ﬁrst 3 months, with
stabilization thereafter. MPA introduction in combination with
CNI minimization, therefore, seems an efﬁcacious and safeJournal of Hepatology 2011approach to limit CNI toxicity and to prevent further renal func-
tion deterioration in the mid-term Table 5.
CNI withdrawal
Several studies have evaluated CNI conversion to MPA [24,52,57–
60] (Table 6) or mTOR inhibitors [61–66] (Table 7).
Introduction of MPA in combination with CNI withdrawal was
generally associated with an improvement in serum creatinine in
60–80% of patients and an increase of GFR by 9–12 ml/min
[24,52,56–60]. However, episodes of graft rejection, reversible or
not, havebeenobserved in3–30%of patients, 12%onaverage. Thus,
in a retrospective analysis ofMPAmonotherapy in 16patients con-
vertedafter amedianof2056 dayspost-LT, three episodes [47, 107,
and 1203 days after conversion] of severe, irreversible graft rejec-
tion were observed. This resulted in death in two patients and
required retransplantation in one patient [67]. In all studies using
MPA monotherapy, there was no pharmacological monitoring of
mycophenolic acid (the active form ofMPA) blood levels, although
signiﬁcant inter-individual and intra-individual variability in the
pharmacokinetics is well established [68].
Interestingly, three studies in the mid-nineties also explored
the efﬁcacy and safety of azathioprine after CNI reduction/inter-
ruption [69–72] in patients with renal impairment. Although lim-
ited, this experiment suggested here again that CNI interruption
under the control of antiproliferative agents was associated with
an improvement in renal function at the cost of rejection. Ran-
domized controlled trials directly comparing azathioprine and
MPA monotherapy in LT recipients with impaired renal function
had never been designed.vol. 54 j 1041–1054 1049
Table 7. CNI withdrawal and replacement by Sirolimus/Everolimus.
foemiTngiseDNecnerefeR
IS change 
Baseline Creatinine Baseline 
GFR 
(ml/mn)
Follow up % of pts with 
renal function
improvement *
Rejection*
N (%) 
13/14
40  
S/C:
20/20
Prospective 
randomized 
controlled 
≥6 months ld/gm5.1 64 0921
ry1tasn
2/20 (5) 
114  
S/C: 
57/57
evitcepsorteR ≥63 months 8173DN 97
ns
)5(
179  
S/C:  
79/100  
Retrospective  
Case-control
Case-control
≥2 months ld/gm2.1 ND  24 ns at 2 yrs )2.1(97/1
21  Prospective 
uncontrolled  
62 months 1.79 ± 0.39 mg/dl  54.6 ± 12.4 19.8 34 0 
27  
S/C:
Prospective 
randomized 
controlled 
≥11 months 221 mol/L  49.8  12  68
sn
2/13 (17) Watson CJ          
2007  
[63]                  
Sirolimus
Shenoy S            
2007   
[64]            
Sirolimus
Dubay D     
2008  
[66]  
Sirolimus                    
Campbell MS 
2007  
[65]
Sirolimus 
Castroagudin JF  
2009  
[67]               
Everolimus
De Simone P    
9002
[26]
Everolimus 
145  
E:72  
C:73  
Prospective  
randomized  
>12 months  
<60 months
ND  51 ± 11.7 12 tasn 3/72 (4.1) 
21  Prospective 
uncontrolled  
6 years  2.2 mg/dl  34  67 ± 39 17 1/21 (5) Fairbanks KD       
2003  
[62]                 
Sirolimus
6 & 12 months
(months)
CNI, Calcineurin Inhibitors; S, sirolimus; E, everolimus; C, control; IS, immunosuppression; Tx, Transplantation; ND, not determined; ⁄ In mToR inhibitors group. Signiﬁcant
improvement in renal function was inconsistently observed after conversion to mTOR inhibitors with an overall risk of rejection of 11/169 (6.5%) after conversion.
ReviewThe use of mTOR inhibitors has shown contrasting results
(Table 7). Overall, CNI interruption after mTOR inhibitor intro-
duction was associated with a 6.5% incidence of rejection. Several
small, uncontrolled, single-center reports have suggested renal
sparing effects in patients with CNI-induced nephrotoxicity con-
verted to either Sirolimus alone, or Sirolimus in conjunction with
a low-dose CNI regimen [61,73–79]. Yet, recent, usually con-
trolled studies suggest that the advantage of Sirolimus-based
immunosuppression on long-term renal function may be over-
stated [26,61–66]. In an open-label, randomized controlled trial
comparing CNI-based immunosuppression to Sirolimus-based
immunosuppression in patients with post-transplant CNI-related
nephrotoxicity, the difference in absolute GFR between the two
groups was signiﬁcant at 3 months (p = 0.02), but not at
12 months (p = 0.07) [63]. Shenoy et al. in a prospective compar-
ison of Sirolimus conversion with unmodiﬁed immunosuppres-
sion in a similar population showed an early (3 month)
signiﬁcant improvement in creatinine clearance. However, this
was not maintained at 1-year [63]. In a case-control study of LT
recipients with relatively preserved renal function, Campbell1050 Journal of Hepatology 2011et al. showed the risk of renal dysfunction after a median fol-
low-up of 1-year was similar whether the patients were switched
to Sirolimus or maintained on CNI [64]. Finally, in a retrospective
case-control series [65], 57 patients with renal insufﬁciency who
had been started on Sirolimus >90 days postoperatively and trea-
ted longer than 90 days were compared to 57 matched patients
maintained on low-dose CNI. At 1 year post-intervention, creati-
nine clearance, rates of progression to renal replacement therapy,
rejection, and death did not differ between the groups. Further-
more, an overall increased prevalence of side-effects in the Sirol-
imus group was observed.
Data about the efﬁcacy and safety of Everolimus in LT recipi-
ents are scarce and inconclusive. In a prospective open-label
study, 21 liver transplant recipients with chronic renal dysfunc-
tion were switched from CNI to Everolimus [66]. A signiﬁcant
improvement in creatinine clearance (Cockroft and Gault) with-
out any rejection episode was observed at 1-year: 54.6 ± 12.4 to
64.4 ± 16.7 ml/min. By contrast, a prospective, randomized, mul-
ticenter study evaluated the impact of Everolimus with CNI
reduction or discontinuation on renal function in maintenancevol. 54 j 1041–1054
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liver transplant recipients with CNI-related renal dysfunction
[26]. The mean change in creatinine clearance from baseline to
month-6 (2 and 3 ml/mn, respectively) was similar between the
two groups (72 Everolimus and 73 control). In addition, study
drug discontinuation was higher in Everolimus patients due to
a higher incidence of adverse events.
Of note, the recent CONVERT trial in kidney transplant recipi-
ents [80] demonstrated that conversion from CNI to Sirolimus
was beneﬁcial in the subgroup of patients with GFR >40 ml/mn
at baseline. In patients with more severe alterations in renal func-
tion, the switch to Sirolimus was associated with more adverse
events and more frequent proteinuria. Pre-existing proteinuria
was also a risk factor for poor outcomes. These results indicate that
in patients with already advanced renal dysfunction, mTOR inhib-
itors are also nephrotoxic, and that in the setting of kidney trans-
plantation, a substantial number of patients actually develop
proteinuria when converted to Sirolimus [81]. In vitro studies sug-
gest that glomerular proteinuriamay reﬂect direct Sirolimus toxic-
ity to the glomerular podocyte–endothelial axis through inhibition
of vascular endothelial growth factor [82]. Impairment in tubular
uptake of protein has also been postulated to be a mechanism for
proteinuria. Unfortunately, one can assume that these ﬁndings
could be extrapolated to liver transplant recipients. Thus conver-
sion to mTOR inhibitors may be only attempted in LT recipients
with GFR >40 ml/mn and with no, or mild proteinuria (<0.8 g/L).
Tailoring immunosuppression to co-morbidities
 As stated above, renal function deterioration often results
from amultifactorial process and is more frequent in patients
withHCV infectionpost-LT.An important issue is, therefore, to
determinewhether immunosuppressioncanbe tailored to the
individual proﬁle of thepatient toprotect thekidney. This par-
ticular aspect has been poorly studied so far.Liver Transplant
No renal injury
in the mid-term 
Close follow-up
Creatinine /Proteinuria/ 
microalbuminuria
+ rapid CNI minimization
± MPA
Consider early of mTOR 
introduction inhibitors
dellortnocdezimodnaR(
trials in progress)
Mild to moder
renal injury
(Stage 2-3)
noitaziminimINC
+  mTOR inhibitors
Or mTOR inhibitor
+ CNI withdrawal +
In the setting of ran
slairtdellortnoc
Fig. 5. Immunosuppressive strategies after liver transplantation: an algorithm for
ﬁltration rate; MPA, mycophenolate acid.
Journal of Hepatology 2011 In patients with HCV recurrence, it is assumed that renal
deterioration is accelerated by latent membranoproliferative
glomerulonephritis often pre-existing LT [83] or detected
post-LT [84]. This results in a higher incidence of signiﬁcant
proteinuria in HCV + compared to HCV-LT recipients [85].
Some preliminary results indicate that treatment of HCV
infection can result in stabilization [86] or improvement
[87] of renal dysfunction and cryoglobulinemia-related
symptoms.
 Twostudies also suggested that the combinationofMPA + CNI
minimization can slow down renal function deterioration in
HCV + LT recipients [88,89]. In one study [88], 19 patients
were assigned to MPA introduction and CsA tapering or to
CsA alone. Renal function improved signiﬁcantly (serum cre-
atinine: 239.3 ± 90.2 versus 175.8 ± 46.0 lmol/L; p = 0.008)
in the treatmentgroup,whiledeteriorating (serumcreatinine:
156.8 ± 44.6 versus 214.8 ± 120.1 lmol/L; p = 0.06) in the
controls.
 In another studycomparing4946HCV + recipientsdischarged
with a triple immunosuppressive regimen containing MPA
and3884HCV + patients receivingadual immunosuppressive
regimen without MPA [89], the risk for post-transplant renal
dysfunction and death was evaluated after controlling for
baseline characteristics and extended steroid use. At 3-years
post-transplant, triple drug therapy was associated with a
6% lower adjusted risk of renal dysfunction. Death rate and
adjusted risk for death were also lower for recipients on a
three- versus two-drug regimen.
 There is currently no evidence indicating that a speciﬁc
immunosuppressive regimen can be protective to the kidney
in case of diabetes or hypertension. Uncontrolled studies
have suggested that conversion from Tac to Csa in cases of
diabetes can improve glucose metabolism [90] but theation
Early renal injury
Severe 
renal injury
(Stage 4)
CNI minimization
APM+
Caution with mTOR inhibitors 
if GFR <40ml/mn
(risk of proteinuria)
ate 
 
 
s
 MPA
domized 
mid/long term kidney protection. CNI calcineurin inhibitors; GFR, glomerular
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impact on renal function has not been studied in the mid-
term. On the other hand, in Ojo’s study [14] Tac was less
nephrotoxic compared to CsA. Speciﬁc studies aimed at
deﬁning the optimal immunosuppressive regimen in
patients with diabetes or hypertension are, therefore, man-
datory. In patients with cardio-vascular risk factors, mTOR
inhibitors may offer an interesting alternative to CNI due
to their different toxicity proﬁle, to prevent renal
deterioration.
In summary, (Fig. 4), the development of irreversible renal
damage after LT is a frequent and serious problem that impacts
on survival. The best treatment of CNI-induced CKD should be
prophylactic (Fig. 5). With this respect, early conversion to mTOR
inhibitors before the occurrence of signiﬁcant injury is a promis-
ing approach which is currently being investigated in a large
phase III clinical trial, whose mid- and long-term results are
eagerly anticipated. Fig. 5.
In the future, the identiﬁcation of molecular signatures of
operational tolerance [91] could even allow complete withdrawal
of immunosuppressive drugs and optimal prevention in tolerant
patients.
In LT recipients with overt CKD, MPA in combination with CNI
minimization seems to be a safe approach that usually results in a
signiﬁcant, although modest, improvement in renal function or at
least stabilization. This is even true in HCV patients.
MPA monotherapy after CNI withdrawal is considered too
risky due to a 12–15% risk of rejection, but safety could be
improved by pharmacological monitoring of MPA [68], an
approach which is currently under investigation [92].
Late CNI withdrawal and conversion to mTOR inhibitors has
achieved variable results in the mid-term, although sometimes
disappointing due to matters of tolerability, or because with-
drawal was attempted in patients already with advanced kidney
damage. Thus in patients with GRF <40 ml/mn, minimization of
CNI under the protection of MPA can be considered less risky
(Fig. 5).Conclusions
Renal dysfunction has emerged as one of the most important
issues in the short, medium, and long term after LT because
of the signiﬁcant impact on survival. Manipulation of immuno-
suppression to avoid or limit CNI nephrotoxicity is one of the
major tools to overcome this problem. Delayed introduction
of CNI in the post-operative phase under the protection of
induction therapy plus MPA in high risk patients and early
withdrawal of CNI under the protection of mTOR inhibitors
are two approaches that could be easily implemented to pre-
vent irreversible renal damage. Their impact on survival
requires further investigation. The role of co-stimulation block-
ade as a CNI sparing regimen and the impact on kidney func-
tion also deserve study. Among the large cohorts of LT
recipients with preexisting signiﬁcant renal function impair-
ment, minimization of CNI, and introduction of MPA currently
offer the best risk/beneﬁt ratio. However, new policies based
on early CNI withdrawal/minimization and conversion to mTOR
inhibitors are promising approaches that could radically change
the management of LT recipients in the future.1052 Journal of Hepatology 2011Key points Conﬂict of interest
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